Discover the top 10 EDR tools for CIOs in 2025 that enhance endpoint protection, accelerate threat investigations, and reduce ...
Hosted on MSN
Harmony Biosciences Phase 3 Study Misses Endpoint
Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Harmony Biosciences Holdings ( (HRMY)) ...
COMPANY NEWS: New Point of Presence Enhances Web application and API protection with low latency and delivers Industry-Leading Threat Prevention and Cloud-Ready Security Architecture Check Point ...
Investing.com -- Harmony Biosciences Holdings (NASDAQ:HRMY) stock dropped 8% Wednesday after the company announced its Phase 3 clinical trial for ZYN002 in Fragile X syndrome failed to meet its ...
Harmony Biosciences (HRMY) announced topline results from its Phase 3 registrational clinical trial of ZYN002 in Fragile X syndrome. The RECONNECT study did not meet the primary endpoint of ...
Cybersecurity solutions provider Check Point Software Technologies has added Enterprise Browser to its Harmony SASE offering. The new feature is designed to extend Zero Trust security to unmanaged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback